TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$174 Million

Five Prime Therapeutics

Follow-on Offering

Lead Left Bookrunner, November 2020

Five Prime Therapeutics

Five Prime Therapeutics is a clinical-stage biotechnology company developing immune modulators and precision therapies to improve the lives of patients with solid tumor cancers. Each of the Company’s product candidates has an innovative mechanism of action and addresses patient populations for which better therapies are needed. In addition, Five Prime uses companion diagnostics where appropriate to allow the Company to select patients most likely to benefit from treatment with its product candidates. Five Prime’s lead product candidate, bemarituzumab (bema), is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, and that induces antibody-dependent cell-mediated cytotoxicity. It is being studied as a treatment for patients with FGFR2b+, non-HER2+ gastric (stomach) or gastroesophageal junction, or GEJ, cancer.